The idea was great. The timing was not.
In early 2026, a health tech founder approached me with a proof of concept she had built using an AWS grant: an AI-driven clinical trial patient matching platform designed for newly diagnosed cancer patients. The concept was genuinely compelling. It targeted a real gap in the market: direct-to-patient trial education and matching, focused initially on young-onset colorectal cancer, a population where incidence has doubled since the 1990s and where trial access remains frustratingly poor.
The founder had built something with real promise. Her product concepts included an adaptive questioning engine, lifestyle-aware matching that accounted for fertility, career impact, and visit logistics, and a vision for making clinical trial protocols genuinely readable by patients. The strategic positioning was sound: a "consumer solution" in a market dominated by enterprise tools that patients never see.
She engaged me to evaluate the platform's viability and develop a business strategy to take it from funded POC to market entry. Over the course of the engagement, I delivered a comprehensive body of strategic work: competitive intelligence, product benchmarking, business model and revenue architecture, brand identity, funding strategy, patient advocacy partnership mapping, and a structured go/no-go decision framework.
The outcome? She decided not to proceed. And that decision was exactly the right one.
What the engagement covered
This was not a surface-level review. The engagement was structured around the first three months of a gated go/no-go framework, and it produced a substantial portfolio of strategic deliverables designed to give the founder the evidence base she needed to make an informed decision about the platform's future.
Competitive intelligence and market positioning
I conducted an independent analysis of over 20 platforms across the clinical trial matching landscape, segmenting the market into patient-facing, provider-facing, and sponsor-facing tools. This included a feature-by-feature comparison matrix, M&A trend tracking, and identification of key white-space opportunities. The research drew on company disclosures, peer-reviewed literature (including a 2025 prospective evaluation published in npj Precision Oncology), and industry reporting from sources including JAMIA, Fierce Healthcare, and CB Insights.
The analysis confirmed the founder's core insight: no existing platform combined patient-centric accessibility with high-fidelity AI matching. The patient-facing segment was the least consolidated portion of the market, and several of her product concepts addressed gaps that no competitor had filled. At the same time, the research revealed that well-funded incumbents were actively expanding toward patient-centric features on top of mature, data-rich platforms.
Product benchmarking and technical assessment
I reviewed the platform's AWS POC materials, the adaptive trial-matching demo, the patient scenario design documentation, and the user acceptance testing results. The UAT review revealed that the matching engine, while functional as a proof of concept, needed significant rebuilding before the platform could deliver clinical-grade accuracy. Key areas requiring development included anatomic site specificity, disease stage mapping, treatment history logic, and patient pathway routing.
These accuracy challenges are not unusual at the POC stage. The published literature shows that even established tools achieve modest precision and recall scores. But the rebuild required to reach market-ready accuracy was a substantial undertaking that needed to be honestly scoped and resourced.
Business model design and revenue architecture
The founder had developed a sound initial business model built around pharmaceutical companies as buyers, using per-patient success fees and trial licensing. The pricing benchmarks were directionally correct and well-aligned with industry data. However, relying exclusively on pharma as the sole buyer carried a structural risk: when pharmaceutical sponsors are the only revenue source, the incentive to prioritize their trials over potentially better-fitting investigator-initiated studies creates a tension with the product's patient-first mission. This is a recognized concern across the trial recruitment industry and addressing it proactively would strengthen both the platform's credibility and its defensibility.
I evolved the business model into a diversified four-layer revenue architecture: health-system licensing as the primary revenue source, firewalled sponsor analytics as secondary revenue, advocacy-group partnerships for mission-aligned distribution, and payer/public-program funding as a growth-stage layer. This included unit economics analysis, pricing benchmarks validated against industry data, and revised three-year financial projections built on diversified revenue rather than dependence on a single buyer class.
Patient advocacy partnerships: a creative distribution and funding strategy
One of the most distinctive elements of this engagement was the development of a patient advocacy partnership strategy that served simultaneously as a distribution channel, a credibility mechanism, and a non-traditional funding pathway.
Most clinical trial technology ventures approach funding through conventional channels: venture capital, pharma partnerships, or government grants written by the startup itself. I took a different approach, researching how patient advocacy organizations in oncology could become active partners in the platform's development and deployment.
Major advocacy organizations strongly want tools like this, but most cannot sustain recurring SaaS-level fees from their own budgets. What they can provide is far more valuable: trust, patient access, co-design credibility, and the ability to embed technology costs into funded research project budgets as trial infrastructure. Several of the organizations I identified invest tens of millions annually in cancer research and actively fund digital tools that improve trial enrollment and patient navigation.
This led to a concrete beachhead strategy: embed the trial-matching tool on advocacy organization websites as a co-branded "find trials near you" resource for newly diagnosed patients, funded through research grants rather than direct licensing fees. The advocacy partnerships would simultaneously drive patient volume and strengthen the value proposition to health systems and sponsors. I mapped specific US and EU oncology advocacy organizations with the funding capacity, patient reach, and mission alignment to support this model, and developed practical next steps for outreach.
For founders in health tech, this type of thinking matters. The most creative go-to-market strategies often come from looking beyond the obvious buyer and asking: who else has the mission alignment, the patient relationships, and the funding mechanisms to make this work?
Brand identity exploration
While the founder reviewed the assessment and worked through the self-assessment checklist, I continued developing operational foundations that would be needed if the decision was to proceed. This included a comprehensive brand identity analysis: competitive naming landscape review, multilingual pronunciation testing, USPTO trademark conflict screening, domain and SEO assessment, and directory positioning. The work produced a tiered shortlist with documented rationale and elimination records for rejected options.
Operating budget
A Year 1 operating budget is a critical early-stage asset to frame decision-making. I built a formula-driven workbook with editable assumptions, monthly cash flow projections, and scenario modeling. It covered team compensation (including sweat equity valuation), infrastructure, software, professional services, compliance, and sales and marketing, designed so a founder could walk through it with a funder and adjust assumptions in real time. This established how much fuel would be needed.
Funding and investment strategy
I mapped non-dilutive and equity funding routes across both the US and EU. The analysis examined NIH SBIR/STTR grants, NSF SBIR Digital Health, the G-BA Innovation Fund, BMBF and EIT Health programmes, and the DiGA fast-track pathway, among others. I recommended a US-first funding strategy: the English-language MVP aligned most naturally with US federal grant options and the US clinical trial ecosystem, where the beachhead advocacy partners were also based. EU sources remained viable but were better suited to a later stage when the platform could support multilingual deployment and European clinical partnerships.
Structured go/no-go decision framework
The capstone deliverable was a 24-page comprehensive assessment report with an accompanying founder response checklist. The report integrated the competitive intelligence, product benchmarking, and business model analysis into a unified strategic picture, and concluded with a gated decision framework across three phases: technical viability (months 0–3), market validation (months 3–6), and commercial readiness (months 6–12). Each gate had specific, measurable criteria that needed to be met before committing additional resources, along with clear discontinuation criteria that would apply at any stage.
The companion checklist translated these gates into concrete questions the founder needed to answer honestly: about team capacity, technical resources, budget feasibility, and personal commitment to the level of effort required.
The gravity of the gap
The founder began completing the self-assessment checklist. The process did exactly what it was designed to do: it surfaced an honest accounting of the gap between what the market required and what could realistically be committed.
The competitive intelligence showed a market accelerating rapidly, with well-funded incumbents advancing in both product capability and marketing maturity. The assessment made clear that the level of effort required to compete across technical rebuild, business development, fundraising, and partnership cultivation exceeded what the founding team could realistically resource at that stage.
The founder made the decision to discontinue the effort. It was a clear-eyed, disciplined call, made early enough to prevent the misallocation of months of time and significant financial resources toward a venture that could not reach the execution velocity the market demanded.
Why a no-go decision is a success story
In the health tech startup world, the default mode is forward motion. Founders pour time, money, and emotional energy into products they believe in, and the sunk-cost fallacy is powerful. The pressure to "just keep going" can lead to months or years of incremental investment in a venture that lacks the structural conditions to succeed.
A rigorous, evidence-based assessment changes the equation. It replaces intuition with data. It replaces optimism with honest benchmarking. And sometimes, it gives a founder the clarity and the permission to stop, not because the idea was bad, but because the conditions required to execute it are not in place.
In this case, the assessment delivered several forms of tangible value:
- Time preserved. Months of effort that would have been spent on fundraising, partnership outreach, and product development for a platform whose core technology needed more investment than the team could provide were redirected to more productive pursuits.
- Capital protected. A fundraising effort was not launched for a venture that could not yet pass its own Gate 1 technical viability criteria.
- Relationships maintained. An early, honest assessment prevented the kind of slow-motion disillusionment that damages founder relationships and professional reputations.
- Strategic clarity gained. The founder now has a comprehensive, evidence-based picture of the competitive landscape, the business model challenges, and the execution requirements. That is intellectual capital that informs any future health tech venture she pursues.
- Decision made with confidence. Rather than wondering "what if," the founder made a data-driven choice she could stand behind.
The work behind a confident "no"
Making a disciplined no-go decision requires more work, not less, than deciding to proceed. Continuing is the path of least resistance; it asks only for optimism and momentum. Stopping asks for evidence, structure, and the willingness to confront what the data is saying.
This engagement required deep immersion in the clinical trial technology landscape, rigorous product benchmarking against published validation data, original business model design, creative partnership and funding strategy development, cross-border funding analysis, and the development of a structured decision framework that could surface the truth about execution readiness. This is the same depth of work needed for ventures that proceed to market entry, because you cannot know which outcome is right until the analysis is complete.
The founder described the assessment as providing the clarity she needed to make a prudent decision. That clarity is the deliverable. Whether the answer is "go" or "not now; not this," the value lies in knowing, with confidence, which one it is. And sometimes, the smartest way to fuel your next move is to stop burning resources on the wrong one.
About ClinTech Strategy Partners
ClinTech Strategy Partners advises health tech startups on commercialization strategy, pharma market readiness, and operational scaling. Principal Karen Maduschke brings nearly 20 years of experience in clinical trial technology, including working on a team that built an early eConsent platform, navigating two acquisitions through to IQVIA, and leading global delivery operations serving over 60 pharmaceutical clients.
Wondering whether your health tech product is ready for its next stage? Take the Pharma Readiness Assessment or schedule a call to discuss where you are.
